NCT05231785
A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
The 50 most recent of 52 versions: 17 with changes below, 33 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Site details revised at 1 of 8 sites
- Notable Eligibility criteria expanded, about 7 words
- Primary and study completion moved earlier from Apr 20, 2029 to Jan 11, 2029
- Secondary endpoints: details revised at 1 of 5 entries
- Minor Primary and study completion dates: Mar 28, 2029 to Apr 20, 2029
- Site details revised at 4 of 8 sites
- Minor Site details revised at 8 of 8 sitesv42
- Notable Primary and study completion dates pushed to Mar 28, 2029v37
Show 12 earlier versionsHide 12 earlier versions
- Minor Study completion date: Jul 1, 2027 to Mar 1, 2029v34
- Minor Site details revised at 1 of 8 sitesv32
- Minor Study sites: 7 to 8v29
- Minor Primary completion date: Jul 2025 to Jul 1, 2025
- Study completion date: Jul 2027 to Jul 1, 2027
- Notable Eligibility criteria expanded, about 9 words
- Study sites: 5 to 7
- Study completion date: Jul 2025 to Jul 2027
- Secondary endpoints revised (5)
- Minor Study sites: 6 to 5v24
- Minor Study sites: 7 to 6v22
- Minor Study sites: 6 to 7v18
- Minor Site details revised at 2 of 6 sitesv15
- Minor Study sites: 4 to 6v12
- Minor Study sites: 2 to 4v8
- Minor Study sites: 1 to 2v6
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Part A: Frequency of Adverse Events
Timeframe: Up to 12 months
Part B: Frequency of Adverse Events
Timeframe: Up to 42 months
Secondary (5)
Part A and Part B: Change from Baseline in Levels of Cerebrospinal Fluid (CSF) Soluble Amyloid Precursor Protein Alpha (sAPPα) and Soluble Amyloid Precursor Protein Beta (sAPPβ)
Part A and Part B: Area Under the Plasma Concentration-time Curve (AUC) of ALN-APP and of Potential Metabolites
Part A and Part B: Maximum Observed Plasma Concentration (Cmax) of ALN-APP and of Potential Metabolites
Part A: Fraction of ALN-APP and Potential Metabolites Excreted in the Urine (fe)
Part A and Part B: Concentration of ALN-APP and Potential Metabolites at Time 't' (Ct) in Plasma and CSF
Arms and interventions
Part A: ALN-APPExperimental
Participants will be administered a single dose of ALN-APP.
Part A: PlaceboPlacebo comparator
Participants will be administered a single dose of placebo.
Part B:Experimental
Participants will be administered multiple doses of ALN-APP.
Drugs: ALN-APP, Placebo
Sites
8 sites in 4 countries
Canada 2, Netherlands 2, United Kingdom 2, United States 2